This is a working overview of HGF mimetic, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-26 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
=== Legal status === It was approved in both the European Union (brand name Revestive) and the United States (brand name Gattex) in 2012. It was granted orphan drug designation by the European Medicines Agency (EMA).
Thereafter, the (16C) acyl-ACP is hydrolyzed by a thioesterase to form one molecule of palmitate and one molecule of ACP. Stoichiometry for the synthesis of palmitate is described by the following equation: 8 Acetyl-CoA + 7 ATP + 14 NADPH + 13 H+ → Palmitate + 14 NADP+ + 8 CoA + 6 H2O + 7 ADP + 7 Pi Throughout the cycle, seven ATP molecules are used for the conversion of seven acetyl-CoA molecules into seven molecules of malonyl-CoA, which is used as the substrate for chain elongation. Hence, the seven molecules of malonyl-CoA are omitted from the stoichiometric equation, given that they were originally derived from acetyl-CoA.
In 2004, the Human Sciences Research Council found that 78% of the respondents thought of homosexuality as unacceptable. Corrective rape is on the rise in South Africa. More than 10 lesbians are raped weekly to "correct" their sexual preferences, as estimated by Luleki Sizwe, a South African nonprofit. It is estimated that at least 500 lesbians become victims of corrective rape every year and that 86% of black lesbians in the Western Cape live in fear of being sexually assaulted, as reported by the Triangle Project in 2008. Yet, victims of corrective rape are less likely to report it because of the negative social view of homosexuality. Under-reporting is high for sexually violent crimes, thus the number of corrective rapes are likely higher than what is reported. Although it is thought to be uncommon, men also become victims of corrective rape. A study conducted by OUT LGBT Well-being and the University of South Africa Centre for Applied Psychology (UCAP) showed that "the percentage of black gay men who said they have experienced corrective rape matched that of the black lesbians who partook in the study". However, not all men admit to being victims of corrective rape. One South African man stated, "Lesbians get raped and killed because it is accepted by our community and by our culture." Kekelesto explained that her experience as "where men try to turn you into a real African woman" and that she was being taught how to be a Black woman.
=== Kwabena Bannerman === Kwabena Bannerman (Toheeb Jimoh) is an associate trader of Ghanaian descent working for Harper’s short-only fund at Mostyn Asset Management. He and Harper are casually involved, though his laidback temperament contrasts with her intensity and single-minded focus on the business. During her controversial short of porn aggregator Siren, Harper has Kwabena draft a forceful email to investors denying redemption requests. She later recruits him to join her new fund, SternTao, but liquidates his other positions to meet a margin call from Deutsche Bank. Kwabena travels to Accra with Sweetpea to investigate Tender’s operations; using family connections, he secures a meeting that helps them uncover falsified profits and recycled revenue at a local payment processor Tender had acquired. Harper presents their findings at an investment conference, triggering a 28% drop in Tender’s stock. The Tender short ultimately nets £110 million, with Harper, Sweetpea, and Kwabena distributing £2 million each and scouting a new office for the fund. Kwabena accompanies Harper to Paris for a political fundraiser hosted by Yasmin but skips the dinner and later admits to Harper that he danced intimately with another woman that night and felt no guilt, questioning the emotional detachment in their relationship and her refusal to confront him about sleeping with Sweetpea. Harper acknowledges she avoids intimacy as self-protection, while Kwabena argues that isolating herself from those closest to her comes at too high a cost.
Sources: en.wikipedia.org
A quantity may decay via two or more different processes simultaneously. In general, these processes (often called "decay modes", "decay channels", "decay routes" etc.) have different probabilities of occurring, and thus occur at different rates with different half-lives, in parallel. The total decay rate of the quantity N is given by the sum of the decay routes; thus, in the case of two processes:
=== Fossil fuels === The HIC of oil, gas and coal is an important geochemical tool to study the formation, storage, migration and many other processes. The HIC signal of fossil fuels results from both inheritance of source material and water as well as fractionations during hydrocarbon generation and subsequent alteration by processes such as isotopic exchange or biodegradation. When interpreting HIC data of sedimentary organic matter one must take all the processes that might have an isotope effect into consideration. Almost all the organic hydrogen is exchangeable to some extent. Isotopic exchange of organic hydrogen will reorder the distribution of deuterium and often incorporate external hydrogen. Generally, more mature materials are more heavily exchanged. With effective exchange, aliphatic hydrogen can finally reach isotopic equilibrium at the final stage. Equilibrium fractionation factor varies between hydrogen sites. For example, aliphatic hydrogen isotope fractionation depends on the carbon atom that the hydrogen atom bonds with. To first order, alkyl HIC follows this trend: δDPrimary carbon < δDSecondary carbon < δDTertiary carbon. The fractionation factors between carbon sites also decrease with increasing temperature. This can be potentially used as a thermo-history indicator. The fractionation between whole molecule and water can be estimated by averaging all hydrogen-positions, and this leads to a relatively small variation of equilibrium fractionation between different groups of hydrocarbons and water.
The chemical energy stored in ATP (the bond of its third phosphate group to the rest of the molecule can be broken, allowing more stable products to form, thereby releasing energy for use by the cell) can then be used to drive processes requiring energy, including biosynthesis, locomotion, or transportation of molecules across cell membranes.
Sources: en.wikipedia.org
== Occupational exposure == Occupational exposure to PFAS occurs in numerous industries due to the widespread use of the chemicals in products and as an element of industrial process streams. People who are exposed to PFAS through their jobs typically have higher blood concentrations of PFAS than the general population due to their elevated risk for accidental ingestion, inhalation exposure, and skin contact of PFAS. Occupational exposure can occur both during production of PFAS at fluorochemical facilities and in other industries that utilize these chemicals in their processes and products.
=== 20 May === Russia claimed to have taken the village of Bilohorivka, Luhansk Oblast. Two people were killed in Russian attacks in Kherson and Zaporizhzhia Oblast. Ukrainian missiles hit a Russian military facility near Katerynivka, Luhansk Oblast, causing "powerful" explosions and a fire. The Ukrainians claimed to have killed 13 Russian servicemen in the strike, while 26 others were wounded. One of the wounded was allegedly Colonel General Gennadiy Anashkin, commander of Russia's Southern Military District. Deputy Governor of Kharkiv Oblast Roman Semenukha claimed that Ukraine still controls 60% of Vovchansk. A Russian court sentenced 24-year-old Ilya Baburin to 25 years in prison for treason and plotting an arson attack against a recruitment center in Siberia on behalf of Ukraine and setting fire to a local music school.
At the fifth year, students break into four core or specialized areas of medical laboratory science, namely: medical microbiology/parasitology, chemical pathology/immunology, haematology/blood transfusion science and histopathology/cytopathology. At the end of the fifth year, suitable students are presented for final professional examination by the Medical Laboratory Science Council of Nigeria.
Eventually, the GLP-1 derivatives Mojsov synthesized, without her knowledge were patented as peptides able to prompt the release of insulin, but with Joel Habener as the sole-creator. Mojsov fought to have her name included in patents, with MGH eventually agreeing to amend four patents to include her name and she received her one-third of drug royalties for one year. She has continued to speak up for credit after her collaborators received various awards as new versions of GLP-1 have been approved and grown popular.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.